Every 8-K that ADMA Biologics, Inc. (ADMA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ADMA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ADMA filings page.
ADMA Biologics reported second quarter 2026 results showing modest top-line growth but significantly higher profitability, driven by ASCENIV. Total revenue for the quarter ended June 30, 2026 was $124.4 million, up 2% year-over-year. ASCENIV revenue rose to $102.9 million, a 24% increase, while revenue from another immune globulin product declined 49% year-over-year but improved sequentially from first-quarter trough levels. Gross profit was $86.3 million with a 69% gross margin, compared with 55% a year earlier, reflecting a richer ASCENIV mix and a yield‑enhanced manufacturing process.
GAAP net income for the quarter was $37.8 million and GAAP basic EPS was $0.17, up 11% and 17% year-over-year, respectively. Adjusted net income was $39.0 million and Adjusted EBITDA $61.8 million, up 8% and 22% year-over-year. For the first half of 2026, revenue was $238.9 million; GAAP net income was $83.1 million and Adjusted EBITDA $121.5 million. Cash and cash equivalents increased to $136.0 million at June 30, 2026, supported by $87.8 million of net cash provided by operating activities, alongside substantial share repurchases and higher long‑term debt. The company reiterated its FY2026 financial guidance and highlighted real‑world data from 127 ASCENIV‑treated patients showing reduced infection‑related hospitalizations and healthcare utilization.
ADMA Biologics, Inc. reported voting results from its 2026 Annual Meeting of Stockholders held on June 2, 2026. As of the April 8, 2026 record date, 232,324,283 common shares were outstanding, and 199,267,547 shares were represented virtually or by proxy, constituting a quorum.
Stockholders elected Class I directors Alison C. Finger and Eduardo Rene Salas. Finger received 156,849,830 votes for and 19,376,842 votes withheld, with 23,040,875 broker non-votes. Salas received 171,947,523 votes for and 4,279,149 votes withheld, with the same broker non-votes.
Stockholders also ratified the appointment of KPMG LLP as independent registered public accounting firm for the year ending December 31, 2026, with 198,655,040 votes for, 329,056 against, and 283,451 abstentions. On a non-binding advisory basis, the Say-on-Pay proposal for named executive officer compensation was approved, receiving 168,169,866 votes for, 7,730,690 against, 326,116 abstentions, and 23,040,875 broker non-votes.
ADMA Biologics reported first quarter 2026 results showing flat revenue but sharply higher profitability. Total revenue was $114.5 million, essentially unchanged from $114.8 million a year earlier, as 28% growth in ASCENIV sales to $97.5 million offset a 54% decline in revenue from another immunoglobulin product and lower intermediates revenue.
Gross profit rose to $80.8 million and gross margin expanded to 71% from 53%, helped by a richer ASCENIV mix and prior manufacturing improvements. GAAP net income increased to $45.3 million from $26.9 million, while Adjusted Net Income reached $40.7 million and Adjusted EBITDA was $59.7 million, both growing more than 20% year over year. The company generated $58 million of operating cash flow and ended March 31, 2026 with $138.2 million of cash and cash equivalents.
Management reiterated confidence in ASCENIV demand and updated its full-year 2026 outlook to reflect competitive pressure in the U.S. immunoglobulin and plasma therapies market, while withdrawing longer-term guidance.
ADMA Biologics reports a key regulatory milestone for its ASCENIV immune globulin therapy. The U.S. Food and Drug Administration has approved a supplemental Biologics License Application expanding ASCENIV’s primary humoral immunodeficiency indication to pediatric and adult patients two years of age and older, from a prior minimum age of 12 years. The approval also fulfills the required pediatric post‑marketing commitment and allows updated prescribing information. ASCENIV is a patented, plasma-derived intravenous immune globulin designed to provide antibodies against infections, supported by an established safety profile that includes boxed warnings and detailed precautions typical for IVIG products.
ADMA Biologics filed a current report to furnish a press release responding to a short seller report by Culper Research. The company states it refutes key allegations about its business practices, operations and immune globulin portfolio, especially regarding its ASCENIV therapy for immune-compromised patients.
ADMA highlights that demand and utilization for ASCENIV have grown steadily over the past two years and are at a record high, and that distributor stocking levels align with industry standards and ASCENIV’s long production cycle. The release also reiterates ASCENIV’s FDA-approved indication, manufacturing approach, patent protection and important safety warnings, and provides an overview of ADMA’s broader plasma-derived biologics portfolio and development pipeline.
ADMA Biologics entered a $125 million accelerated share repurchase agreement with JPMorgan Chase Bank as part of its previously authorized $500 million share repurchase program. The company will fund the transaction with borrowings under its existing $225 million revolving credit facility.
ADMA expects to receive about 6.4 million shares of common stock around March 3, 2026, representing roughly 80% of the shares tied to this agreement, based on a closing share price of $15.57 on February 27, 2026. The final share count will depend on the average daily volume‑weighted average price over the ASR term and is expected to be settled within five months, which could result in ADMA receiving additional shares or delivering shares or cash at final settlement.
The company also outlined a 2026 capital return initiative targeting approximately $200 million, noting that, since the program’s May 2025 authorization, prior repurchases plus this ASR represent about $160 million of common stock repurchased. Management highlights sustained revenue growth, expanding margins and anticipated stronger cash flow as support for continuing to invest in growth while returning capital to stockholders.
ADMA Biologics reported record fourth quarter and full year 2025 results and announced a CFO transition. Full year 2025 revenue reached $510.2 million, up 20% from 2024, driven largely by ASCENIV, which generated $362.5 million and grew 51% year over year. Gross profit was $292.8 million with a 57.4% margin, while adjusted net income rose to $160.8 million, up 35%, and adjusted EBITDA increased to $231.0 million, up 40%.
Fourth quarter 2025 revenue was $139.2 million, up 18% year over year, with gross profit of $88.8 million and adjusted EBITDA of $73.6 million. ADMA reaffirmed long-term guidance targeting more than $1.1 billion in annual revenue and greater than $700 million in adjusted EBITDA in 2029. The company also highlighted progress on its SG-001 pipeline program and ongoing share repurchases.
Separately, long-time CFO Brad Tade retired effective February 25, 2026 and will serve as a consultant through July 31, 2026, receiving $41,666.67 per month. He is succeeded by Terry (Paul Terence) Kohler, who becomes Chief Financial Officer and Treasurer with a $500,000 base salary, a 45% target bonus opportunity and equity awards subject to multi-year vesting and change-of-control protections.
ADMA Biologics, Inc. filed a current report describing that it has issued a press release with preliminary, unaudited full year 2025 revenue figures and a broader business update. The company notes that these results are subject to completion of its accounting and annual audit procedures and may change once the audit is finished, so they should be viewed as early estimates rather than final numbers.
ADMA is also making available a Corporate Presentation it expects to use in meetings with potential investors, strategic partners, industry analysts and others. Both the press release and the presentation are provided as exhibits to the report and are described as being furnished, not filed, which means they are not automatically incorporated into other securities law filings unless specifically referenced.
ADMA Biologics (ADMA) furnished a press release announcing financial results for the three months ended September 30, 2025, and a business update. The release is attached as Exhibit 99.1 to an 8‑K dated November 5, 2025. The information under Item 2.02 is expressly stated as furnished, not filed, and is not subject to Section 18 liabilities nor incorporated into other filings unless specifically referenced. ADMA’s common stock trades on the Nasdaq Global Market.